The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study

Satu Mustjoki; Johan Richter; Gisela Barbany; Ingunn Dybedal; Thoas Fioretos; Tobias Gedde Dahl; Bjorn T. Gjertsen; Randi Hovland; Sari Jalkanen; Dag Josefsen; Perttu Koskenvesa; Carin Lassen; Kirsi Latvala; Waleed Majeed; Claes Malm; Berit Markevarn; Ali Moshfegh; Lotta Ohm; Tor Olofsson; Ulla Olsson Stromberg; Katrin Rapakko; Kari Remes; Jesper Stentoft; Leif Stenke; Merja Suominen; Sara Thunberg; Ole Weiss Bjerrum; Bengt Simonsson; Kimmo Porkka; Henrik Hjorth Hansen

The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study

Satu Mustjoki, Johan Richter, Gisela Barbany, Ingunn Dybedal, Thoas Fioretos, Tobias Gedde Dahl, Bjorn T. Gjertsen, Randi Hovland, Sari Jalkanen, Dag Josefsen, Perttu Koskenvesa, Carin Lassen, Kirsi Latvala, Waleed Majeed, Claes Malm, Berit Markevarn, Ali Moshfegh, Lotta Ohm, Tor Olofsson, Ulla Olsson StrombergKatrin Rapakko, Kari Remes, Jesper Stentoft, Leif Stenke, Merja Suominen, Sara Thunberg, Ole Weiss Bjerrum, Bengt Simonsson, Kimmo Porkka, Henrik Hjorth Hansen

Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract › Peer review

Originalspråk	engelska
Sidor (från-till)	291-292
Tidskrift	Blood
Volym	116
Nummer	21
Status	Published - 2010
Evenemang	52nd Annual Meeting of the American-Society-of-Hematology (ASH) - Orlando, FL Varaktighet: 2010 dec. 4 → 2010 dec. 7

Ämnesklassifikation (UKÄ)

Hematologi

Citera det här

Mustjoki, S., Richter, J., Barbany, G., Dybedal, I., Fioretos, T., Dahl, T. G., Gjertsen, B. T., Hovland, R., Jalkanen, S., Josefsen, D., Koskenvesa, P., Lassen, C., Latvala, K., Majeed, W., Malm, C., Markevarn, B., Moshfegh, A., Ohm, L., Olofsson, T., ... Hansen, H. H. (2010). The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study. Blood, 116(21), 291-292.

Mustjoki, Satu ; Richter, Johan ; Barbany, Gisela et al. / The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study. I: Blood. 2010 ; Vol. 116, Nr. 21. s. 291-292.

@article{0439c97c23cb405b8fdc13357548695a,

title = "The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study",

author = "Satu Mustjoki and Johan Richter and Gisela Barbany and Ingunn Dybedal and Thoas Fioretos and Dahl, {Tobias Gedde} and Gjertsen, {Bjorn T.} and Randi Hovland and Sari Jalkanen and Dag Josefsen and Perttu Koskenvesa and Carin Lassen and Kirsi Latvala and Waleed Majeed and Claes Malm and Berit Markevarn and Ali Moshfegh and Lotta Ohm and Tor Olofsson and Stromberg, {Ulla Olsson} and Katrin Rapakko and Kari Remes and Jesper Stentoft and Leif Stenke and Merja Suominen and Sara Thunberg and Bjerrum, {Ole Weiss} and Bengt Simonsson and Kimmo Porkka and Hansen, {Henrik Hjorth}",

year = "2010",

language = "English",

volume = "116",

pages = "291--292",

journal = "Blood",

issn = "1528-0020",

publisher = "American Society of Hematology",

number = "21",

note = "52nd Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 04-12-2010 Through 07-12-2010",

}

Mustjoki, S, Richter, J, Barbany, G, Dybedal, I, Fioretos, T, Dahl, TG, Gjertsen, BT, Hovland, R, Jalkanen, S, Josefsen, D, Koskenvesa, P, Lassen, C, Latvala, K, Majeed, W, Malm, C, Markevarn, B, Moshfegh, A, Ohm, L, Olofsson, T, Stromberg, UO, Rapakko, K, Remes, K, Stentoft, J, Stenke, L, Suominen, M, Thunberg, S, Bjerrum, OW, Simonsson, B, Porkka, K & Hansen, HH 2010, 'The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study', Blood, vol. 116, nr. 21, s. 291-292.

The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study. / Mustjoki, Satu; Richter, Johan; Barbany, Gisela et al.
I: Blood, Vol. 116, Nr. 21, 2010, s. 291-292.

Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract › Peer review

TY - JOUR

T1 - The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study

AU - Mustjoki, Satu

AU - Richter, Johan

AU - Barbany, Gisela

AU - Dybedal, Ingunn

AU - Fioretos, Thoas

AU - Dahl, Tobias Gedde

AU - Gjertsen, Bjorn T.

AU - Hovland, Randi

AU - Jalkanen, Sari

AU - Josefsen, Dag

AU - Koskenvesa, Perttu

AU - Lassen, Carin

AU - Latvala, Kirsi

AU - Majeed, Waleed

AU - Malm, Claes

AU - Markevarn, Berit

AU - Moshfegh, Ali

AU - Ohm, Lotta

AU - Olofsson, Tor

AU - Stromberg, Ulla Olsson

AU - Rapakko, Katrin

AU - Remes, Kari

AU - Stentoft, Jesper

AU - Stenke, Leif

AU - Suominen, Merja

AU - Thunberg, Sara

AU - Bjerrum, Ole Weiss

AU - Simonsson, Bengt

AU - Porkka, Kimmo

AU - Hansen, Henrik Hjorth

PY - 2010

Y1 - 2010

M3 - Published meeting abstract

SN - 1528-0020

VL - 116

SP - 291

EP - 292

JO - Blood

JF - Blood

IS - 21

T2 - 52nd Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 4 December 2010 through 7 December 2010

ER -

Mustjoki S, Richter J, Barbany G, Dybedal I, Fioretos T, Dahl TG et al. The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study. Blood. 2010;116(21):291-292.